Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 2
Submit an article Journal homepage
184
Views
0
CrossRef citations to date
0
Altmetric
Review

Medical management of Cushing’s syndrome

Farah H Morgan Division of Endocrinology, Diabetes & Metabolism, Assistant Professor of Medicine, Cooper Medical School of Rowan University, 1210 Brace Road, Suite 107, Cherry Hill, NJ 08034, USA; Division of Endocrinology, Diabetes & Metabolism, Assistant Professor of Medicine, Cooper Medical School of Rowan University, 1210 Brace Road, Suite 107, Cherry Hill, NJ 08034, USA
&
Marc Laufgraben Division Head, Division of Endocrinology, Diabetes & Metabolism, Associate Professor of Medicine, Cooper Medical School of Rowan University, Cooper University Hospital, 3 Cooper Plaza Suite 220, Camden, NJ 08103, USA. [email protected]; Division Head, Division of Endocrinology, Diabetes & Metabolism, Associate Professor of Medicine, Cooper Medical School of Rowan University, Cooper University Hospital, 3 Cooper Plaza Suite 220, Camden, NJ 08103, USA. [email protected]
Pages 183-193 | Published online: 10 Jan 2014

References

  • BillerBM, GrossmanAB, StewartPM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93(7), 2454–2462 (2008).
  • Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur. J. Endocrinol. 158(1), 91–99 (2008).
  • Sharma ST, Nieman LK. Cushing’s syndrome: all variants, detection, and treatment. Endocrinol. Metab. Clin. North Am. 40(2), 379–391, viii (2011).
  • Castinetti F, Nagai M, Dufour H et al. Gamma Knife radiosurgery is a successful adjunctive treatment in Cushing’s syndrome. Eur. J. Endocrinol. 156, 91–98 (2007).
  • Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing’s disease. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 607–623 (2009).
  • NiemanLK, BillerBM, FindlingJW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93(5), 1526–1540 (2008).
  • Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22(12), 499–506 (2011).
  • Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol. (Oxf.) 40(4), 479–484 (1994).
  • Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin. Endocrinol. (Oxf.) 63(5), 549–559 (2005).
  • ImakiT, TsushimaT, HizukaN et al. Postoperative plasma cortisol levels predict long-term outcome in patients with Cushing’s disease and determine which patients should be treated with pituitary irradiation after surgery. Endocr. J. 48(1), 53–62 (2001).
  • Fleseriu M, Loriaux DL, Ludlam WH. Second-line treatment for Cushing’s disease when initial pituitary surgery is unsuccessful. Curr. Opin. Endocrinol. Diabetes. Obes. 14(4), 323–328 (2007).
  • PrevedelloDM, PouratianN, ShermanJ et al. Management of Cushing’s disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J. Neurosurg. 109(4), 751–759 (2008).
  • FriedmanRB, OldfieldEH, NiemanLK et al. Repeat transsphenoidal surgery for Cushing’s disease. J. Neurosurg. 71(4), 520–527 (1989).
  • Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R. Surgical treatment of recurrent Cushing’s disease. Neurosurgery 58(6), 1108–1118; discussion 1108 (2006).
  • Liu JK, Fleseriu M, Delashaw JB Jr, Ciric IS, Couldwell WT. Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg. Focus 23(3), E8 (2007).
  • Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML. Gamma Knife surgery for Cushing’s disease. J. Neurosurg. 106(6), 980–987 (2007).
  • EstradaJ, BoronatM, MielgoM et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N. Engl. J. Med. 336(3), 172–177 (1997).
  • Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing’s Disease. Clin. Med. Insights Oncol. 6, 75–84 (2012).
  • AssiéG, BahurelH, CosteJ et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J. Clin. Endocrinol. Metab. 92(1), 172–179 (2007).
  • Sonino N. The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. 317(13), 812–818 (1987).
  • PontA, WilliamsPL, LooseDS et al. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med. 97(3), 370–372 (1982).
  • Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 7(4), 409–420 (1986).
  • Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients. Clin. Endocrinol. (Oxf.) 35(4), 347–352 (1991).
  • Mancini T, Porcelli T, Giustina A. Treatment of Cushing disease: overview and recent findings. Ther. Clin. Risk Manag. 6, 505–516 (2010).
  • Nizoral (ketoconazole), package insert. Janssen Pharmaceutica, NJ, USA (2002).
  • Dang CN, Trainer P. Pharmacological management of Cushing’s syndrome: an update. Arq. Bras. Endocrinol. Metabol. 51(8), 1339–1348 (2007).
  • Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing’s disease. Br. Med. J. 2(6081), 215–217 (1977).
  • Orth DN. Metyrapone is useful only as adjunctive therapy in Cushing’s disease. Ann. Intern. Med. 89(1), 128–130 (1978).
  • VerhelstJA, TrainerPJ, HowlettTA et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin. Endocrinol. (Oxf.) 35(2), 169–178 (1991).
  • Luton JP, Mahoudeau JA, Bouchard PH et al. Treatment of Cushing’s disease by O,P’DDD. N. Eng. J. Med. 300, 459–464 (1979).
  • LutonJP, CerdasS, BillaudL et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med. 322(17), 1195–1201 (1990).
  • FassnachtM, TerzoloM, AllolioB et al.; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366(23), 2189–2197 (2012).
  • Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27(27), 4619–4629 (2009).
  • Kamenicky P, Droumaguet C, Salenave S et al. Mitotane, metyrapone and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J. Clin. Endocrinol. Metab. 96, 2796–2804 (2011).
  • Lacroix A. Approach to the patient with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 95(11), 4812–4822 (2010).
  • Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol. Metab. Clin. North Am. 28(1), 211–222 (1999).
  • Santen RJ, Misbin RI. Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy 1(2), 95–120 (1981).
  • Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing’s syndrome. J. Clin. Endocrinol. Metab. 86(9), 4104–4108 (2001).
  • Fleseriu M, Petersenn S. Medical management of Cushing’s disease: what is the future? Pituitary 15(3), 330–341 (2012).
  • Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolemia in Cushing’s syndrome: a review. Eur. J. Endocrinol. 167, 137–143 (2012).
  • Boscaro M, Benato M, Mantero F. Effect of bromocriptine in pituitary-dependent Cushing’s syndrome. Clin. Endocrinol. (Oxf.) 19(4), 485–491 (1983).
  • PivonelloR, FeroneD, de HerderWW et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab. 89(5), 2452–2462 (2004).
  • PivonelloR, De MartinoMC, CappabiancaP et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94(1), 223–230 (2009).
  • Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur. J. Endocrinol. 163(5), 709–716 (2010).
  • Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm. Res. 62(6), 300–305 (2004).
  • de Herder WW, Lamberts SW. Is there a role for somatostatin and its analogs in Cushing’s syndrome? Metab. Clin. Exp. 45(8 Suppl. 1), 83–85 (1996).
  • BatistaDL, ZhangX, GejmanR et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 91(11), 4482–4488 (2006).
  • BoscaroM, LudlamWH, AtkinsonB et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115–122 (2009).
  • ColaoA, PetersennS, Newell-PriceJ et al.; Pasireotide B2305 Study Group. A 12-month Phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012).
  • CastilloV, GiacominiD, Páez-PeredaM et al. Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology 147(9), 4438–4444 (2006).
  • Pecori GiraldiF, AmbrogioAG, AndrioliM et al. Potential role for retinoic acid in patients with Cushing’s disease. J. Clin. Endocrinol. Metab. 97(10), 3577–3583 (2012).
  • Johanssen S, Allolio B. Mifepristone (RU486) in Cushing’s syndrome. Eur. J. Endocrinol. 157, 561–569 (2007).
  • NiemanLK, ChrousosGP, KellnerC et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 61(3), 536–540 (1985).
  • ChrousosGP, LaueL, NiemanLK et al. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney Int. Suppl. 26, S18–S23 (1988).
  • Chrousos GP, Laue L, Nieman L et al. Clinical applications of RU486, a prototype glucocorticoid and progestin antagonist. Raven Press, NY, USA (1989).
  • Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing’s disease with high dose mifepristone (RU486). JCEM 86, 3568–3573 (2001).
  • CastinettiF, FassnachtM, JohanssenS et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur. J. Endocrinol. 160(6), 1003–1010 (2009).
  • Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J. Clin. Endocrinol. Metab. 97(6), 2039–2049 (2012).
  • Korlym (mifepristone), package insert. Corcept Therapeutics, CA, USA (2012).
  • FeeldersRA, de BruinC, PereiraAM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N. Engl. J. Med. 362(19), 1846–1848 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.